Venus Concept, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92332W2044
USD
1.14
-0.04 (-3.39%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

560.44 k

Shareholding (Sep 2025)

FII

0.14%

Held by 5 FIIs

DII

93.89%

Held by 1 DIIs

Promoter

5.33%

How big is Venus Concept, Inc.?

22-Jun-2025

As of Jun 18, Venus Concept, Inc. has a market capitalization of 4.52 million and reported net sales of 61.00 million with a net profit loss of 49.55 million over the last four quarters. The company's shareholder's funds are 2.37 million, and total assets are 68.18 million.

Market Cap: As of Jun 18, Venus Concept, Inc. has a market capitalization of 4.52 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Venus Concept, Inc. reported net sales of 61.00 million. However, the company experienced a net profit loss of 49.55 million during the same period.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 2.37 million, while total assets were reported at 68.18 million.

View full answer

What does Venus Concept, Inc. do?

22-Jun-2025

Venus Concept, Inc. develops and manufactures medical aesthetic devices and operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company. As of March 2025, it reported net sales of $14 million and a net loss of $12 million, with a market cap of $4.52 million.

Overview: <BR>Venus Concept, Inc. develops and manufactures devices for the medical aesthetic market and operates within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 14 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -12 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 4.52 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 14.84 <BR>Return on Equity: -1,641.51% <BR>Price to Book: 2.00<BR><BR>Contact Details: <BR>Address: 235 Yorkland Blvd Suite 900, TORONTO ON: M2J 4Y8 <BR>Tel: 1 408 8836888 <BR>Fax: 1 302 6555049 <BR>Website: http://www.restorationrobotics.com/

View full answer

Should I buy, sell or hold Venus Concept, Inc.?

22-Jun-2025

Who are in the management team of Venus Concept, Inc.?

22-Jun-2025

As of March 2022, the management team of Venus Concept, Inc. includes CEO Domenic Serafino, Directors Keith Sullivan, Scott Barry, Garheng Kong, Louise Lacchin, and Fritz LaPorte.

As of March 2022, the management team of Venus Concept, Inc. includes the following individuals:<BR><BR>- Mr. Domenic Serafino, Chief Executive Officer and Director<BR>- Mr. Keith Sullivan, Director<BR>- Mr. Scott Barry, Independent Director<BR>- Dr. Garheng Kong, Independent Director<BR>- Ms. Louise Lacchin, Independent Director<BR>- Mr. Fritz LaPorte, Independent Director

View full answer

Is Venus Concept, Inc. technically bullish or bearish?

20-Sep-2025

As of August 27, 2025, Venus Concept, Inc. is in a mildly bearish trend, indicated by bearish daily moving averages and monthly Bollinger Bands, while significantly underperforming the S&P 500 with a year-to-date return of -43.50%.

As of 27 August 2025, the technical trend for Venus Concept, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by bearish signals from the daily moving averages and monthly Bollinger Bands, while the weekly and monthly MACD and KST indicators show mild bullishness. The Dow Theory indicates a mildly bearish trend on the monthly timeframe. <BR><BR>In terms of performance, the stock has significantly underperformed against the S&P 500, with a year-to-date return of -43.50% compared to the S&P 500's 12.22%, and a one-year return of -57.67% versus 17.14% for the index.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate 5.04% of over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
2

Flat results in Jun 25

3

Risky - Negative EBITDA

4

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

9.50

stock-summary
Return on Equity

-1,522.41%

stock-summary
Price to Book

1.31

Revenue and Profits:
Net Sales:
14 Million
(Quarterly Results - Sep 2025)
Net Profit:
-23 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-43.0%
0%
-43.0%
6 Months
-53.47%
0%
-53.47%
1 Year
-71.37%
0%
-71.37%
2 Years
-91.97%
0%
-91.97%
3 Years
207.78%
0%
207.78%
4 Years
-99.54%
0%
-99.54%
5 Years
-99.68%
0%
-99.68%

Venus Concept, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-2.05%
EBIT Growth (5y)
5.04%
EBIT to Interest (avg)
-4.58
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
14.84
Sales to Capital Employed (avg)
1.41
Tax Ratio
0.62%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.08%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.00
EV to EBIT
-1.32
EV to EBITDA
-1.52
EV to Capital Employed
1.06
EV to Sales
0.62
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-80.79%
ROE (Latest)
-1641.51%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 2 Schemes (0.64%)

Foreign Institutions

Held by 5 Foreign Institutions (0.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -12.10% vs 15.44% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -92.31% vs 5.65% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "13.80",
          "val2": "15.70",
          "chgp": "-12.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.50",
          "val2": "-8.10",
          "chgp": "-4.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.10",
          "val2": "-1.80",
          "chgp": "-516.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.50",
          "val2": "-11.70",
          "chgp": "-92.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-689.30%",
          "val2": "-576.20%",
          "chgp": "-11.31%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -15.18% vs -23.22% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -27.03% vs 15.14% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "64.80",
          "val2": "76.40",
          "chgp": "-15.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.30",
          "val2": "-24.20",
          "chgp": "3.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.70",
          "val2": "6.90",
          "chgp": "11.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10.60",
          "val2": "-2.00",
          "chgp": "-430.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-47.00",
          "val2": "-37.00",
          "chgp": "-27.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-419.30%",
          "val2": "-370.80%",
          "chgp": "-4.85%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
13.80
15.70
-12.10%
Operating Profit (PBDIT) excl Other Income
-8.50
-8.10
-4.94%
Interest
1.20
1.20
Exceptional Items
-11.10
-1.80
-516.67%
Consolidate Net Profit
-22.50
-11.70
-92.31%
Operating Profit Margin (Excl OI)
-689.30%
-576.20%
-11.31%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is -12.10% vs 15.44% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -92.31% vs 5.65% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
64.80
76.40
-15.18%
Operating Profit (PBDIT) excl Other Income
-23.30
-24.20
3.72%
Interest
7.70
6.90
11.59%
Exceptional Items
-10.60
-2.00
-430.00%
Consolidate Net Profit
-47.00
-37.00
-27.03%
Operating Profit Margin (Excl OI)
-419.30%
-370.80%
-4.85%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -15.18% vs -23.22% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -27.03% vs 15.14% in Dec 2023

stock-summaryCompany CV
About Venus Concept, Inc. stock-summary
stock-summary
Venus Concept, Inc.
Pharmaceuticals & Biotechnology
Venus Concep, Inc., formerly Restoration Robotics, Inc., develops and manufactures devices for the medical aesthetic market. The Company offers a range of products and services under various brands, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, Venus Heal, Venus Skin and Venus Bliss. It offers a product portfolio of minimally invasive and non-invasive medical aesthetic technologies in over 60 countries and 29 direct markets. Its hair restoration division includes NeoGraft, an automated hair restoration system that facilitates the harvesting of follicles during a follicular unit extraction (FUE) process. Venus Viva includes NanoFractional Radio Frequency (RF) and SmartScan technology. It offers aesthetic products for the treatment of face, neck and body. Venus Fiore is designed with three applicators to address internal vaginal health restoration, labia skin tightening and mons pubis reduction.
Company Coordinates stock-summary
Company Details
235 Yorkland Blvd Suite 900 , TORONTO ON : M2J 4Y8
Registrar Details